PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,377,021 | -27.6% | 422,085 | 0.0% | 0.98% | -12.8% |
Q2 2023 | $6,044,257 | +100.6% | 422,085 | 0.0% | 1.12% | +99.6% |
Q1 2023 | $3,013,687 | -36.4% | 422,085 | 0.0% | 0.56% | -9.4% |
Q4 2022 | $4,735,794 | +1.3% | 422,085 | 0.0% | 0.62% | -7.1% |
Q3 2022 | $4,677,000 | +31.3% | 422,085 | 0.0% | 0.66% | +74.5% |
Q2 2022 | $3,562,000 | -38.0% | 422,085 | 0.0% | 0.38% | -11.0% |
Q1 2022 | $5,745,000 | -30.8% | 422,085 | 0.0% | 0.43% | -9.5% |
Q4 2021 | $8,302,000 | -38.7% | 422,085 | 0.0% | 0.47% | -46.1% |
Q3 2021 | $13,549,000 | – | 422,085 | – | 0.88% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |